The Joint Corp.
- Open
- 8.44
- Day high
- 8.53
- Day low
- 8.32
- Prev close
- 8.43
- Volume
- 76K
- Mkt cap
- $119M
- P/E (TTM)
- 31.8
- EPS (TTM)
- $0.27
- P/B
- 7.5
- P/S
- 2.0
- Yield
- —
- Per share
- —
The Joint Corp. (JYNT) is a Healthcare company listed on NASDAQ. The stock is down 21% over the past year.
The Joint Corp. (JYNT) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
JYNT earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 6, 2026 | $0.05 | $-0.01 | -121.4% | $15M | +6.4% |
| May 7, 2026 | $0.03 | $0.08 | +166.7% | $15M | +4.5% |
| Mar 12, 2026 | $0.04 | $0.07 | +69.9% | $15M | +9.4% |
| Nov 6, 2025 | $-0.01 | $0.02 | +300.0% | $13M | -8.8% |
| Aug 7, 2025 | $-0.07 | $-0.06 | +14.3% | $13M | -7.1% |
| May 8, 2025 | $-0.02 | $-0.03 | -50.0% | $13M | +1.4% |
| Mar 13, 2025 | $0.06 | $0.06 | +0.0% | $14M | -48.4% |
| Nov 7, 2024 | $-0.00 | $0.04 | +2731.6% | $30M | +5.4% |
| Aug 8, 2024 | $-0.01 | $-0.06 | -629.9% | $30M | +4.1% |
| May 2, 2024 | $0.01 | $0.06 | +1100.0% | $12M | -58.5% |
| Mar 7, 2024 | $-0.00 | $0.07 | +6350.0% | $13M | -56.6% |
| Nov 9, 2023 | $-0.01 | $-0.05 | -377.6% | $29M | +0.7% |
JYNT insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 12, 2026 | Bowman Scott Justinofficer: Chief Financial Officer | Tax | 1,392 | $8.43 |
| May 22, 2026 | Karrmann Sandra Rdirector | Grant | 5,714 | — |
| May 22, 2026 | Rubel Matthew Edirector | Grant | 5,714 | — |
| May 22, 2026 | DaVella Ronald Vdirector | Grant | 5,714 | — |
| May 22, 2026 | Grandpre Christopher Mdirector | Grant | 5,714 | — |
| May 14, 2026 | JOBSON CHARLES E10 percent owner | Buy | 127,676 | $8.57 |
| May 14, 2026 | JOBSON CHARLES E10 percent owner | Buy | 20,375 | $8.57 |
| Apr 23, 2026 | JOBSON CHARLES E10 percent owner | Buy | 509 | $8.58 |
| Mar 11, 2026 | Razdan Sanjiv Kumardirector, officer: See Remarks | Grant | 73,484 | — |
| Mar 11, 2026 | Bowman Scott Justinofficer: Chief Financial Officer | Grant | 28,301 | — |
| Feb 17, 2026 | JOBSON CHARLES E10 percent owner | Buy | 15,397 | $8.50 |
| Feb 13, 2026 | JOBSON CHARLES E10 percent owner | Buy | 448 | $8.70 |
| Jan 27, 2026 | JOBSON CHARLES E10 percent owner | Buy | 725 | $10.00 |
| Jan 27, 2026 | JOBSON CHARLES E10 percent owner | Buy | 16,753 | $10.00 |
| Jan 8, 2026 | JOBSON CHARLES E10 percent owner | Buy | 5,240 | $8.89 |
Source: JYNT SEC Form 4 filings, latest Jun 12, 2026. For informational purposes only — not investment advice.
See the full JYNT insider & 13F page →The Joint Corp. company profile
Overview
The Joint Corp. (NASDAQ:JYNT) is a healthcare franchisor that operates chiropractic clinics across the United States. Founded in 2010 and headquartered in Scottsdale, Arizona, the company went public in November 2014. The Joint Corp. has built a network of approximately 970 chiropractic clinics nationwide, with about 87% operating under franchise agreements. The company is currently undergoing a strategic transformation to become a pure-play franchisor by selling off its remaining corporate-owned clinics, a process it aims to complete by the end of 2025.
Business
The Joint Corp. operates in the chiropractic healthcare industry, providing accessible and affordable chiropractic care through a retail-oriented clinic model. Chiropractic care is a form of alternative medicine that focuses on diagnosing and treating neuromuscular disorders, with particular emphasis on treating these disorders through manual adjustment and manipulation of the spine. Traditional chiropractic care often requires appointments weeks in advance and can be expensive, but The Joint has revolutionized this model. The company's core offering is convenient, walk-in chiropractic care that eliminates many barriers associated with traditional chiropractic services. Patients can visit Joint clinics without appointments, receive treatment in a streamlined environment, and access care at more affordable price points than traditional chiropractic offices. The clinics are typically located in high-traffic retail locations like strip malls and shopping centers, making them easily accessible to consumers. The Joint operates through two primary business segments: 1. Franchise Operations (approximately 75-80% of revenue): This segment generates revenue through initial franchise fees, ongoing royalty fees (typically 7% of gross sales), marketing fund contributions, and technology fees from franchisees. The company provides franchisees with operational support, marketing assistance, and standardized clinic formats. 2. Corporate Clinics (approximately 20-25% of revenue): These are company-owned and operated clinics that generate revenue directly from patient visits and membership fees. However, the company is actively selling these corporate clinics to franchisees as part of its strategic transformation. The company's service model centers around membership-based recurring revenue, with approximately 85% of system-wide sales coming from monthly membership plans rather than single-visit fees. This creates predictable revenue streams and encourages patient retention.
Competitive moat
The Joint Corp. possesses a moderate competitive moat primarily built on brand recognition, operational standardization, and network effects within the chiropractic industry. The company has established itself as the largest chiropractic franchise system in the United States, creating brand awareness that differentiates it from independent chiropractic practices. This brand recognition helps attract both patients seeking familiar, reliable service and potential franchisees looking for proven business models. The company's standardized operational model creates efficiency advantages through its "clinic-in-a-box" concept, streamlined patient flow processes, and centralized marketing support. These standardizations reduce franchisee risk and improve unit economics compared to independent practices. The membership-based model also creates switching costs for patients and generates predictable recurring revenue streams. However, The Joint's moat faces significant challenges. The chiropractic industry has low barriers to entry, as licensed chiropractors can easily establish independent practices or join competing franchise systems. The company competes not only with other chiropractic franchises but also with independent practitioners, physical therapy clinics, massage therapy services, and emerging wellness concepts. Regulatory risks in healthcare could impact the industry, and changing insurance reimbursement policies could affect patient demand. The company's competitive position is also vulnerable to consumer economic sensitivity, as chiropractic care is often considered discretionary healthcare spending. Digital marketing effectiveness, crucial for patient acquisition, depends on constantly evolving online platforms and algorithms beyond the company's control. While The Joint has achieved scale advantages, its moat is not particularly deep or durable compared to companies with stronger network effects, switching costs, or regulatory protections.
Risks & safety
The Joint Corp. presents a moderate margin of safety with manageable debt levels but elevated valuation metrics and recent operational challenges. • Liquidity and Solvency: Strong cash position of $21.9 million with current ratio of 1.59x, indicating adequate short-term liquidity. Low debt-to-equity ratio of 0.11x shows minimal financial leverage risk. • Cash Flow Concerns: Negative operating cash flow of -$3.7 million and free cash flow of -$4.0 million in Q1 2025 raise near-term sustainability questions, though this may reflect transition costs from refranchising. • Valuation Metrics: Elevated P/E ratio of 59.2x and EV/EBITDA of 36.1x suggest high valuation relative to current earnings power. Price-to-book ratio of 9.5x indicates significant premium to tangible assets. • Operational Metrics: Revenue growth of 7% with modest EBITDA margins indicate the business model is functioning but not generating strong profitability during the transition period. • Strategic Transition Risk: The ongoing refranchising process creates execution risk, though management has signed letters of intent for 93% of corporate clinics, suggesting high probability of completion.
Recent development
Over the past few years, The Joint Corp. has undergone significant strategic transformation under its "Joint 2.0" initiative. The most significant development is the company's decision to become a pure-play franchisor by selling substantially all of its corporate-owned clinics to franchisees. This refranchising process began in earnest in 2023 and accelerated through 2024-2025, with management signing letters of intent for 93% of corporate clinics as of Q1 2025. The company has invested heavily in technology and digital capabilities to improve patient experience and operational efficiency. Key technological initiatives include launching an initial visit booking system, implementing digital intake forms, developing a consumer-facing mobile app (launched by June 2025), and introducing dynamic revenue management systems for optimized pricing strategies. Marketing transformation has been another major focus, with the hiring of a new Chief Marketing Officer and shift toward digital marketing channels including social media platforms like TikTok. The company has moved away from traditional advertising toward awareness and consideration campaigns, influencer marketing, and targeted digital strategies to improve new patient acquisition and conversion rates. Under new CEO Sanjiv Razdan, who joined in 2024, the company has emphasized operational excellence through improved patient care protocols, strengthened clinic economics, and enhanced franchisee support systems. The "clinic-in-a-box" concept has been refined to reduce build-out costs and time-to-market for new locations. The company has also begun exploring potential expansion into adjacent services and B2B opportunities while maintaining focus on its core chiropractic offering.
JYNT company profile · for informational purposes only — not investment advice.
Track JYNT with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free